VistaGen Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for anxiety, depression and certain additional central nervous system disorders. Co.'s product candidates include: PH94B, which is a neuroactive nasal spray with therapeutic potential in a range of indications involving anxiety or phobia; PH10, which is a synthetic neurosteroid delivered intranasally that has therapeutic potential in a range of neuropsychiatric indications involving depression; and AV-101 (4-Cl-KYN), which is an oral prodrug that targets the N-methyl-D-aspartate receptor, an ionotropic glutamate receptor in the brain. The VTGN stock yearly return is shown above.
The yearly return on the VTGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VTGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|